No benefit for personalized education, risk assessment performed during ophthalmologic visits
FRIDAY, May 22, 2015 (HealthDay News) — For patients with diabetes, personalized education and diabetes risk assessments performed during retinal ophthalmologic visits do not result in improved glycemic control, according to a study published online May 21 in JAMA Ophthalmology.
Lloyd Paul Aiello, M.D., Ph.D., from Harvard Medical School in Boston, and colleagues examined whether point-of-care hemoglobin A1c (HbA1c) measurement and personalized diabetes risk assessments performed during retinal ophthalmologic visits improve glycemic control. Investigators from 42 sites were randomized to provide study-prescribed augmented diabetes assessment and education or usual care. Participants were adults with type 1 or 2 diabetes who were classified according to the frequency of follow-up care: those receiving a more-frequent-than-annual follow-up (502 control and 488 intervention participants) and those receiving annual follow-up (368 control and 388 intervention participants).
The researchers found that the mean change in HbA1c was −0.1 and −0.3 percent, respectively, in the control and intervention groups at one year (P = 0.35) among participants with more-frequent-than-annual follow-up. The mean change in HbA1c was 0.0 and −0.1 percent, respectively, for the control and intervention groups (P = 0.63) at one year among the cohort with annual follow-ups. Similar results were seen for all secondary outcomes.
“These data suggest that optimizing glycemic control remains a substantive challenge requiring interventional paradigms other than those examined in our study,” the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
Full Text (subscription or payment may be required)
Copyright © 2015 HealthDay. All rights reserved.